169504-53-4 Usage
Uses
Used in Pharmaceutical Industry:
3,4-dihydro-1-[(4-methoxyphenyl)methyl]-1H-1,4-Benzodiazepine-2,5-dione is used as a medication for the treatment of insomnia due to its ability to enhance the effects of GABA, leading to a calming effect and promoting sleep.
Used in Sleep Aid Applications:
Flurazepam is used as a sleep aid for individuals suffering from insomnia, helping to reduce the overactivity of certain brain cells and induce a calming effect that facilitates sleep.
Used in Short-term Treatment:
Due to its potential for abuse and addiction, as well as its sedative effects, 3,4-dihydro-1-[(4-methoxyphenyl)methyl]-1H-1,4-Benzodiazepine-2,5-dione is used for short-term treatment of insomnia, ensuring that patients receive the necessary relief without the risk of long-term dependency.
Used with Caution in Substance Abuse History:
Flurazepam is used with caution in individuals with a history of substance abuse, as its potential for abuse and addiction may pose a risk to these patients. Careful monitoring and dosage adjustments may be necessary to ensure safe and effective treatment.
Used in Combination with Other CNS Depressants:
When used in conjunction with other central nervous system depressants, 3,4-dihydro-1-[(4-methoxyphenyl)methyl]-1H-1,4-Benzodiazepine-2,5-dione requires careful consideration and monitoring, as the combined sedative effects may increase the risk of adverse reactions or complications.
Check Digit Verification of cas no
The CAS Registry Mumber 169504-53-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,5,0 and 4 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 169504-53:
(8*1)+(7*6)+(6*9)+(5*5)+(4*0)+(3*4)+(2*5)+(1*3)=154
154 % 10 = 4
So 169504-53-4 is a valid CAS Registry Number.
169504-53-4Relevant academic research and scientific papers
BENZODIAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C
-
, (2011/12/14)
The invention concerns benzodiazepine derivatives of Formula (I) wherein A, X, L1, L2, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment or prophylaxis of hepatitis C virus infection.
New synthesis of 1,3-dihydro-1,4-benzodiazepin-2(2H)-ones and 3-amino-1,3-dihydro-1,4-benzodiazepin-2(2H)-ones: Pd-catalyzed cross-coupling of imidoyl chlorides with organoboronic acids
Nadin, Alan,Sanchez Lopez, Jose M.,Owens, Andrew P.,Howells, Dean M.,Talbot, Adam C.,Harrison, Timothy
, p. 2844 - 2852 (2007/10/03)
A new approach to the synthesis of 1,4-benzodiazepines and 3-amino-1,4-benzodiazepines, which employs the Pd-catalyzed cross-coupling reaction of an imidoyl chloride with an organometallic reagent as the key step, is described. A five-step synthesis of a
